[
  {
    "ts": null,
    "headline": "Biotech stocks slide as Marks resignation seen being negative for sector",
    "summary": "Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit",
    "url": "https://finnhub.io/api/news?id=254d158cbf2c958ffa39dd784453958618f4931103736807bbadab76abc44dcf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743522637,
      "headline": "Biotech stocks slide as Marks resignation seen being negative for sector",
      "id": 133645467,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit",
      "url": "https://finnhub.io/api/news?id=254d158cbf2c958ffa39dd784453958618f4931103736807bbadab76abc44dcf"
    }
  },
  {
    "ts": null,
    "headline": "GILD or AMGN: Which Is the Better Value Stock Right Now?",
    "summary": "GILD vs. AMGN: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=4a606a31dbc49f767cf9afc7f05806d74555d9134bd2e4120d87627ed51612d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743522007,
      "headline": "GILD or AMGN: Which Is the Better Value Stock Right Now?",
      "id": 133655234,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "GILD vs. AMGN: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=4a606a31dbc49f767cf9afc7f05806d74555d9134bd2e4120d87627ed51612d3"
    }
  },
  {
    "ts": null,
    "headline": "Discovering a Breakthrough: Gilead’s Long-Standing Commitment to Helping Change the Course of HIV",
    "summary": "NORTHAMPTON, MA / ACCESS Newswire / April 1, 2025 / In 2006, Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground around the globe and existing therapies were limited. He was 12 years ...",
    "url": "https://finnhub.io/api/news?id=a4a4595109d42c1c0bde63836635ad06185f62e912184556c4c3139a8e126882",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743512100,
      "headline": "Discovering a Breakthrough: Gilead’s Long-Standing Commitment to Helping Change the Course of HIV",
      "id": 133645419,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "NORTHAMPTON, MA / ACCESS Newswire / April 1, 2025 / In 2006, Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground around the globe and existing therapies were limited. He was 12 years ...",
      "url": "https://finnhub.io/api/news?id=a4a4595109d42c1c0bde63836635ad06185f62e912184556c4c3139a8e126882"
    }
  },
  {
    "ts": null,
    "headline": "Impax U.S. Sustainable Economy Fund Q4 2024 Commentary",
    "summary": "During the fourth quarter of 2024, the US International Sustainable Economy portfolio underperformed the Russell 1000 benchmark. Read more here.",
    "url": "https://finnhub.io/api/news?id=99d9b8efe5edf830404917aa0e1ce4cd2992cf5577f50da15928e27fd6c873e4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743507120,
      "headline": "Impax U.S. Sustainable Economy Fund Q4 2024 Commentary",
      "id": 133644643,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1481194928/image_1481194928.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "During the fourth quarter of 2024, the US International Sustainable Economy portfolio underperformed the Russell 1000 benchmark. Read more here.",
      "url": "https://finnhub.io/api/news?id=99d9b8efe5edf830404917aa0e1ce4cd2992cf5577f50da15928e27fd6c873e4"
    }
  },
  {
    "ts": null,
    "headline": "These biotech names aren't facing 'huge concern' from tariffs",
    "summary": "Trump's upcoming tariffs has the potential to bring biopharma manufacturing to the US, which could impact companies with overseas production. Jefferies managing director Michael Yee joins Market Domination Overtime to discuss how tariffs could impact the biotech sector, emphasizing Vertex (VRTX), Amgen (AMGN), and Gilead (GILD) as some of his top large-cap picks in the sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.",
    "url": "https://finnhub.io/api/news?id=3c95152d520015603efbbfe60d018817dd7753417c24b8ffe43796a8e6ed66ce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743507025,
      "headline": "These biotech names aren't facing 'huge concern' from tariffs",
      "id": 133645380,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Trump's upcoming tariffs has the potential to bring biopharma manufacturing to the US, which could impact companies with overseas production. Jefferies managing director Michael Yee joins Market Domination Overtime to discuss how tariffs could impact the biotech sector, emphasizing Vertex (VRTX), Amgen (AMGN), and Gilead (GILD) as some of his top large-cap picks in the sector. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.",
      "url": "https://finnhub.io/api/news?id=3c95152d520015603efbbfe60d018817dd7753417c24b8ffe43796a8e6ed66ce"
    }
  },
  {
    "ts": null,
    "headline": "Discovering a Breakthrough: Gilead's Long-Standing Commitment to Helping Change the Course of HIV",
    "summary": "In 2006, Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground around the globe and existing therapies were limited. He was 12 years...",
    "url": "https://finnhub.io/api/news?id=888bbbfbeee98738840f3691d7f3d7ff2555d9e0e3a7ffe0232785ad4049da7d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743498612,
      "headline": "Discovering a Breakthrough: Gilead's Long-Standing Commitment to Helping Change the Course of HIV",
      "id": 133635173,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "In 2006, Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground around the globe and existing therapies were limited. He was 12 years...",
      "url": "https://finnhub.io/api/news?id=888bbbfbeee98738840f3691d7f3d7ff2555d9e0e3a7ffe0232785ad4049da7d"
    }
  },
  {
    "ts": null,
    "headline": "Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company",
    "summary": "Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider investing in CORT stock.",
    "url": "https://finnhub.io/api/news?id=6d3999a58f1fa9a321b0c9d56bd51dbd5f295b378e3787266cd5533d0cd47cfc",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743491721,
      "headline": "Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company",
      "id": 133634442,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2164256928/image_2164256928.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider investing in CORT stock.",
      "url": "https://finnhub.io/api/news?id=6d3999a58f1fa9a321b0c9d56bd51dbd5f295b378e3787266cd5533d0cd47cfc"
    }
  }
]